SARS-CoV-2/COVID-19: Funding Opportunities & Agency Guidance

Funding opportunities related to SARS-CoV-2/COVID-19. 

Last updated: January 11, 2021 2:30 PM.


GrantForward Covid-19 list of opportunities

GrantForward is providing free access to available coronavirus-related funding calls. The list is updated on a daily basis

Agency for Healthcare Research and Quality (AHRQ)

NEW AHRQ Releases Two Future Funding Opportunities for COVID-19 Responsiveness

AHRQ has released two Notices of Intent for upcoming funding opportunities designed to support studies evaluating health system and healthcare professional responsiveness to COVID-19.  The agency plans to publish notices calling for both urgent revision supplements to existing AHRQ grants, and for novel high-impact studies to be funded through the R01 mechanism.

  • Competitive revision supplements for existing AHRQ projects should “capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the on-going research to develop high-impact new knowledge concerning COVID-19.”  AHRQ expects to make at least $2.5 million available for these supplements and will release the full solicitation in April 2020.
  • For new studies related to COVID-19, AHRQ is interested in “innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic,” with a particular focus on digital health innovation and meeting the needs of vulnerable populations.  AHRQ expects to dedicate $5 million to this program. A full solicitation will be released in early May 2020, with an expected deadline in June 2020.

Air Force Office of Sponsored Programs

Guidance for Coronavirus Disease 2019 (COVID-19) No Cost Extensions (NCEs):

American Heart Association

The American Heart Association is offering fast-tracked research grants for short-term projects that can turn around results within 9-12 months to better understand the diagnosis, prevention, treatment and clinical management of COVID-19 as it relates to heart and brain health. Application and more information.


National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)


DOE Office of Science Memorandum to Applicants and Awardees

Health and Human Services (HHS) Office of Biomedical Advanced Research and Development Authority (BARDA)

The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), issued the BAA, BAA-18-100-SOL-00003-Amendment 13, to solicit proposals for advanced development and licensure of COVID-19 diagnostics, vaccines, or medicines such as therapeutics or antivirals.

HHS BARDA has revised its Broad Agency Announcement (BAA) to only accept proposals and white papers in areas relevant to the study of COVID-19.

Areas of interest include:

  • AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
  • AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
  • AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
  • AOI 8.3 COVID-19 Vaccine
  • AOI 9.2 COVID-19 Therapeutics
  • AOI 9.3 Immunomodulators or therapeutics targeting lung repair
  • AOI 9.5 Pre-exposure and post-exposure prophylaxis
  • AOI 10 Respiratory protective devices
  • AOI 11 Ventilators
  • AOI 17 Advanced Manufacturing Technologies



Office of Management and Budget (OMB)

OMB has issued a memo providing “Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly Impacted by the Novel Coronavirus (COVID-19)".